A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.
- 03 May 2017 Planned initiation date changed from 15 Mar 2017 to 6 Jun 2017.
- 02 Feb 2017 New trial record